Amgen And AstraZeneca Highlight Data To Be Presented At 22nd Congress Of The European Academy Of Dermatology And Venereology

 Amgen And AstraZeneca Highlight Data To Be Presented At 22nd Congress Of The
               European Academy Of Dermatology And Venereology

PR Newswire

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., Oct. 3, 2013

THOUSAND OAKS, Calif.and GAITHERSBURG, Md., Oct. 3, 2013 /PRNewswire/
--Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and
development arm MedImmune, today announced the upcoming presentation of
several key studies evaluating brodalumab, a human monoclonal antibody
targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate
to severe psoriasis at the 22^nd Congress of the European Academy of
Dermatology and Venereology (EADV) in Istanbul, Oct. 2-6, 2013.

"The Phase 2 data demonstrate that the primary and secondary end points were
met, including many patients achieving and maintaining total skin clearance
with continued brodalumab therapy," said Sean E. Harper, M.D., executive vice
president of Research and Development at Amgen. "We look forward to further
investigating brodalumab for patients with moderate to severe psoriasis."

Dr. Bahija Jallal, executive vice president, MedImmune added, "We're very
encouraged by these results and the initiation of our Phase 3 program."

In Oct. 2012, the companies announced the start of the Phase 3 program in
moderate to severe psoriasis for brodalumab. The program consists of three
Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab
and/or placebo.

Abstracts will be presented during the poster session on Friday, Oct. 4, 2013.

Abstracts of Interest Include:

  oMaintenance of Clinical Response with Long-Term Brodalumab (AMG 827)
    Therapy for Psoriasis: Week 96 Results from an Open-Label Extension Study
    (Poster IST13-0686)
  oDifference in Health-Related Quality of Life (HRQoL) with Increased
    Improvements in Psoriasis Area and Severity Index (PASI) and Maintenance
    of Skin Clearance (Poster 1030)
  oImpact of Treatment with Brodalumab on Psoriasis Symptom Severity: Use of
    a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory
    (PSI) (Poster 1640)

About Brodalumab (AMG 827)

Brodalumab is a highly-selective human monoclonal antibody that binds to and
blocks signaling via the interleukin-17 (IL-17) receptor. The IL-17 pathway
plays an important role in inducing and promoting inflammatory disease
processes. Blocking inflammatory signaling at the IL-17 receptor may be
beneficial in the treatment of moderate to severe plaque psoriasis, psoriatic
arthritis, and potentially other immune-mediated diseases.

About Amgen

Amgenis committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgenfocuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since
1980,Amgenhas grown to be the world's largest independent biotechnology
company, has reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.

For more information, and follow us

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit:

About MedImmune

MedImmune is the worldwide biologics research and development arm of
AstraZeneca. MedImmune is pioneering innovative research and exploring novel
pathways across key therapeutic areas, including respiratory, inflammation and
autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience;
and infection and vaccines. The MedImmune headquarters is located in
Gaithersburg, Md., one of AstraZeneca's three global R&D centers. For more
information, please visit

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on
Amgen's current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the

Securities and Exchange Commission (SEC) reports filed by Amgen, including
Amgen's most recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms
10-K, 10-Q and 8-K for additional information on the uncertainties and risk
factors related to Amgen's business. Unless otherwise noted, Amgen is
providing this information as of Oct. 2, 2013 and expressly disclaims any duty
to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen projects. Discovery or identification of new
product candidates or development of new indications for existing products
cannot be guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product candidate
or development of a new indication for an existing product will be successful
and become a commercial product. Further, preclinical results do not
guarantee safe and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal models. The
length of time that it takes for Amgen to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and Amgen
expects similar variability in the future. Amgen develops product candidates
internally and through licensing collaborations, partnerships and joint
ventures. Product candidates that are derived from relationships may be
subject to disputes between the parties or may prove to be not as effective or
as safe as Amgen may have believed at the time of entering into such
relationship. Also, Amgen or others could identify safety, side effects or
manufacturing problems with Amgen's products after they are on the market.
Amgen's business may be impacted by government investigations, litigation and
product liability claims. If we fail to meet the compliance obligations in
the corporate integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Amgen depends on third parties for a
significant portion of its manufacturing capacity for the supply of certain of
its current and future products and limits on supply may constrain sales of
certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement
policies imposed by third-party payers, including governments, private
insurance plans and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international trends
toward managed care and healthcare cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement. Government
and others' regulations and reimbursement policies may affect the development,
usage and pricing of Amgen's products. In addition, Amgen competes with other
companies with respect to some of its marketed products as well as for the
discovery and development of new products. Amgen believes that some of its
newer products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Amgen's
products may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or that are
otherwise competitive with its products. In addition, while Amgen routinely
obtains patents for its products and technology, the protection offered by its
patents and patent applications may be challenged, invalidated or circumvented
by its competitors and there can be no guarantee of Amgen's ability to obtain
or maintain patent protection for its products or product candidates. Amgen
cannot guarantee that it will be able to produce commercially successful
products or maintain the commercial success of its existing products. Amgen's
stock price may be affected by actual or perceived market opportunity,
competitive position, and success or failure of its products or product
candidates. Further, the discovery of significant problems with a product
similar to one of Amgen's products that implicate an entire class of products
could have a material adverse effect on sales of the affected products and on
Amgen's business and results of operations.

The scientific information discussed in this news release related to Amgen's
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

CONTACT: MedImmune / AstraZeneca
Tracy Rossin, 301-398-1468 (media)
Karl Hard, +44 20 7604 812 (investors)
Colleen Proctor, 302-886-1842 (investors)




Press spacebar to pause and continue. Press esc to stop.